Here is the latest from Tom in Ohio. Turns out he had a bit of a scare late last week: The great scholar Mike Tyson once said "everyone has a plan until they get punched in the face". This week was one long “punch in the face,” but the plan is back on track. I
Deciding to undergo a risky and experimental therapy like an allegeneic (donor) stem cell transplant isn't an easy decision for a multiple myeloma patient, their family and doctor to make. What were the factors that went into Tom's decision to transplant later this month? Let me let Tom explain in his own words: "The allo
Tom was Diagnosed at age 37 during a routine physical. His CBC showed an elevated white blood count, and slightly decreased hemoglobin. According to Tom, “My primary doc has always been a details kind of guy, so he dug and found my IGG was high. He immediately sent me to a Myeloma Specialist.” Good catch!
I would like you to meet Tom. Like many of us, Tom is a multiple myeloma survivor. But unlike most of us, Tom was diagnosed unusually young. And his myeloma has proved to be very aggressive. So Tom and his doctors recently decided to take a brave and unproven step: to undergo an allogeneic (donor)
A few days back I ran a post about how improvements in the way allogeneic transplants are administered may help reduce the number and severity of side-effects: Mini allogeneic (donor) transplants may turn-out to be great salvage therapy option In my post, I refer to some experimentation that lead Moffitt Cancer Center BMT doc, Mellissa
It was easy to become a bit discouraged as I wrote my book last year, Stem Cell Transplants from a Patient's Perspective. As I interviews lots of donor transplant patients, it didn't take long to figure out that their side-effects were significant and long lasting. But I did speak with a few that tried mini
One of our regular readers, named Mark, forwarded me this exciting new abstract of a transplant study which will be presented at this year's ASH meetings in San Diego: Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma To make a long story short, here